Stocks · News reference
Madrigal Pharmaceuticals announced it will present multiple abstracts, including new real-world evidence for its MASH treatment Rezdiffra, at the upcoming AASLD The Liver Meeting.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a
Goldman Sachs analyst Andrea Newkirk reinstates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and announces $704 price target.
Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and announces Price Target of $725.